(UroToday.com) The 2026 GU ASCO annual meeting featured a kidney cancer trials in progress session and a presentation by Dr. Laurence Albiges discussing REJOICE-PanTumor01, a phase 2 signal-seeking ...
Patients with advanced clear cell RCC whose disease progressed after 1-3 prior systemic therapies (including an anti–PD- [L]1 therapy) were randomly assigned 1:1 to belzutifan 200 mg or 120 mg daily: ...
The 2026 GU ASCO annual meeting featured a testicular cancer session and a presentation by Dr. Jennifer King discussing a ...
An optimal PSA response, defined as ≤0.2 ng/mL, is achieved by approximately 51% of mHSPC patients 6–8 months after treatment with androgen deprivation therapy (ADT) and androgen receptor pathway ...
Safety and efficacy evaluation of nadofaragene firadenovec instilled into the renal pelvis in subjects with low-grade upper tract urothelial carcinoma (LG-UTUC): A single-arm, open-label phase 1/2 ...
These data represent the first published dosimetry data for our investigational formulation of Lu-177 zadavotide guraxetan, with projected mean cumulative renal doses remaining low for a six-cycle ...
Cancer. https://doi.org/10.1002/cncr.35612, December 2024. Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review ...
Founded by a multidisciplinary team of experts, US Prostate Cancer Conferences seeks to connect thought leaders from academia, community practice, and industry to accelerate progress in the diagnosis, ...
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
Over the past half-century, global fertility rates have declined, with the Western Pacific Region (WPR) experiencing a particularly notable drop. A recent World Health Organisation-commissioned report ...
Male infertility is a prevalent global health issue, with urological disorders representing some of the most common and correctable causes. Key conditions such as varicocele, obstructive azoospermia, ...
Alan Wein: Hello, it's Alan Wein from UroToday. And today we have a special treat for you all the way from Japan, Professor Yoshiyuki Akiyama, who's the professor and chair of the Department of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results